INDIANAPOLIS, June 9, 2019 /PRNewswire/ — Detailed outcomes from REWIND, the Trulicity® (dulaglutide) cardiovascular end result trial, confirmed a major 12 p.c discount in main cardiovascular occasions (MACE), a composite endpoint of non-fatal myocardial infarction (coronary heart assault), non-fatal stroke or CV demise. REWIND information confirmed a constant MACE Three impact in folks with and with out established CV illness. The CV threat discount was sustained all through the trial’s period.1 The extremely anticipated information for Eli Lilly and Firm’s (NYSE: LLY) once-weekly Trulicity have been introduced throughout a symposium as we speak on the American Diabetes Affiliation’s® 79th Scientific Periods® and concurrently printed in The Lancet.1
REWIND is the longest cardiovascular end result trial within the GLP-1 receptor agonist class (median 5.four years) and consisted primarily of individuals with out established CV illness. Whereas all individuals had CV threat elements, solely 31 p.c of research individuals had established CV illness. The research additionally had one of many lowest median baseline A1Cs of any diabetes CV end result trial to this point (7.2 p.c) and had a balanced ratio of girls (46.Three p.c) to males (53.7 p.c). This affected person inhabitants is extra consultant of individuals with kind 2 diabetes usually seen in medical follow.2
“Dulaglutide is the primary kind 2 diabetes drugs to considerably scale back main opposed cardiovascular occasions (MACE Three) in a research inhabitants the place the vast majority of individuals had CV threat elements with out established CV illness,” stated Hertzel Gerstein, M.D., MSc, FRCPC, professor of drugs and deputy director of the Inhabitants Well being Institute at McMaster College and Hamilton Well being Sciences, and REWIND research chair. “REWIND confirmed that including dulaglutide to the therapeutic routine of kind 2 diabetes will profit a broad vary of individuals.”
REWIND in contrast the impact of Trulicity 1.5 mg to placebo, each along with commonplace of care, on the danger of MACE Three in 9,901 adults with kind 2 diabetes. The danger discount proven by Trulicity for the general research (HR=Zero.88, 95% CI: Zero.79-Zero.99) was constant throughout subgroups, together with: 1
established heart problems: HR=Zero.87, 95% CI: Zero.74-1.02;
no established heart problems: HR=Zero.87, 95% CI: Zero.74-1.02;
baseline A1C larger than or equal to 7.2 p.c: HR=Zero.86, 95% CI: Zero.74-1.00;
baseline A1C lower than 7.2 p.c: HR=Zero.90, 95% CI: Zero.76-1.06;
girls: HR=Zero.85, 95% CI: Zero.71-1.02; and
males: HR=Zero.90, 95% CI: Zero.79-1.04.
All three elements contributed to the numerous discount Trulicity supplied in MACE Three, together with CV demise (HR=Zero.91, 95% CI: Zero.78-1.06), non-fatal coronary heart assault (HR=Zero.96, 95% CI: Zero.79-1.16) and non-fatal stroke (HR=Zero.76, 95% CI: Zero.61-Zero.95). Trulicity additional confirmed reductions in composite microvascular outcomes (HR=Zero.87, 95% CI: Zero.79-Zero.95), characterised by fewer composite renal outcomes.1 Evaluation of the renal outcomes suggests long-term Trulicity use was related to decreased development of renal illness in folks with kind 2 diabetes.Three
Along with the long-term follow-up assessing CV outcomes, REWIND supplies extra proof of Trulicity’s efficacy in treating diabetes. Trulicity decreased A1C throughout the research from a median baseline of seven.2 p.c in comparison with placebo (A1C: -Zero.46 p.c [Trulicity], +Zero.16 p.c [placebo]; Weight: -2.95 kg [Trulicity], -1.49 kg [placebo]). 1
Trulicity’s security profile was according to the GLP-1 receptor agonist class. The commonest opposed occasions resulting in the discontinuation of Trulicity have been gastrointestinal occasions.1
“Trulicity is already well-known for serving to folks with kind 2 diabetes attain their blood glucose targets with a weekly dose,” stated Brad Woodward, M.D., international improvement chief, Incretins, Lilly. “Detailed outcomes from our landmark REWIND trial display a cardiovascular profit in a extra consultant inhabitants of individuals with kind 2 diabetes. These information counsel Trulicity might help physicians and other people with kind 2 diabetes higher handle blood glucose and cardiovascular threat over the long-term.”
The REWIND outcomes have been submitted to regulatory authorities within the U.S. and Europe for evaluate.
Lilly will host an investor name Monday, June 10, at 10:00 a.m. EDT (7:00 a.m. PDT) to debate the corporate’s displays on the American Diabetes Affiliation’s 79th Scientific Periods.
In regards to the REWIND Research
REWIND (Researching cardiovascular Occasions with a Weekly INcretin in Diabetes) was a multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate the impact of Trulicity 1.5 mg, a weekly glucagon-like peptide 1 receptor agonist (GLP-1 RA), in comparison with placebo, each added to straightforward of care (in line with native commonplace of care pointers), on cardiovascular (CV) occasions in adults with kind 2 diabetes. The first CV end result was the primary prevalence of MACE (the composite of CV demise or non-fatal myocardial infarction or non-fatal stroke). Secondary outcomes embrace every part of the first composite CV end result, a composite medical microvascular end result comprising retinal or renal illness, hospitalization for unstable angina, coronary heart failure requiring hospitalization or an pressing coronary heart failure go to, and all-cause mortality. The 9,901 individuals from 24 international locations had a imply period of diabetes of 10.5 years and a median baseline A1C of seven.2 p.c. Whereas all individuals had CV threat elements, solely 31 p.c of the research individuals had established CV illness. Prior (or established) heart problems in REWIND was outlined as prior myocardial infarction, prior ischemic stroke, prior unstable angina, prior revascularization (coronary, carotid, or peripheral), prior hospitalization for ischemia-related occasions (unstable angina or myocardial ischemia on imaging, or want for percutaneous coronary intervention), or prior documented myocardial ischemia.
The REWIND trial’s worldwide scope, excessive proportion of girls, excessive proportion of individuals with out established heart problems and inclusion of individuals with a decrease imply baseline A1C counsel that the findings shall be instantly related to the everyday kind 2 diabetes affected person seen generally follow all through the world.
Indication and Limitations of Use for Trulicity®
Trulicity is a once-weekly injectable prescription drugs to enhance blood sugar (glucose) in adults with kind 2 diabetes mellitus. It must be used together with weight loss plan and train. Trulicity just isn’t really useful as the primary remedy to deal with diabetes. It has not been studied in individuals who have had irritation of the pancreas (pancreatitis). Trulicity shouldn’t be utilized by folks with kind 1 diabetes, folks with diabetic ketoacidosis, or folks with a historical past of extreme gastrointestinal (GI) illness. It isn’t an alternative to insulin. It has not been studied in kids below 18 years of age.
Essential Security Data for Trulicity®
Sufferers ought to inform their healthcare supplier in the event that they get a lump or swelling of their neck, have hoarseness, bother swallowing, or shortness of breath whereas taking Trulicity. These could also be signs of thyroid most cancers. In research with rats or mice, Trulicity and medicines that work like Trulicity precipitated thyroid tumors, together with thyroid most cancers. It isn’t identified if Trulicity will trigger thyroid tumors or a kind of thyroid most cancers referred to as medullary thyroid carcinoma (MTC) in folks. Sufferers shouldn’t take Trulicity in the event that they or any of their relations have ever had MTC or if they’ve A number of Endocrine Neoplasia syndrome kind 2 (MEN 2).
Sufferers shouldn’t take Trulicity if they’ve had an allergic response to dulaglutide or any of the opposite components in Trulicity.
Trulicity shouldn’t be utilized in kids below 18 years of age.
Trulicity might trigger severe unwanted effects, together with:
Irritation of the pancreas (pancreatitis). If a affected person has ache of their abdomen space (stomach) that’s extreme and won’t go away, they need to cease taking Trulicity and name their healthcare supplier immediately. The ache might occur with or with out vomiting. It could be felt going from the stomach by means of to the again.
Low blood sugar (hypoglycemia). If sufferers are utilizing one other drugs that may trigger low blood sugar (equivalent to insulin or a sulfonylurea) whereas taking Trulicity, their threat for getting low blood sugar (hypoglycemia) could also be greater. Indicators and signs of low blood sugar might embrace dizziness, blurred imaginative and prescient, anxiousness, irritability, temper modifications, sweating, slurred speech, starvation, confusion or drowsiness, shakiness, weak spot, headache, quick heartbeat, or feeling jittery. Sufferers ought to discuss to their healthcare supplier about low blood sugar and easy methods to handle it.
Severe allergic reactions. Sufferers ought to cease taking Trulicity and get medical assist immediately if they’ve signs of a severe allergic response together with: swelling of the face, lips, tongue or throat; issues respiration or swallowing; extreme rash or itching; fainting or feeling dizzy; or very speedy heartbeat.
Acute kidney damage. In individuals who have kidney issues, diarrhea, nausea, and vomiting might trigger a lack of fluids (dehydration). This may increasingly trigger kidney issues to worsen.
Extreme abdomen issues. Trulicity might trigger abdomen issues, which could possibly be extreme.
Sufferers ought to inform their healthcare supplier in the event that they:
have or have had issues with their pancreas, kidneys, or liver.
have extreme issues with their abdomen, equivalent to slowed emptying of the abdomen (gastroparesis) or issues with digesting meals.
have another medical situations.
are pregnant or plan to turn into pregnant, or in the event that they turn into pregnant whereas taking Trulicity. It isn’t identified if Trulicity will hurt their unborn child.
are breastfeeding or plan to breastfeed. It isn’t identified if Trulicity passes into breast milk. Sufferers shouldn’t use Trulicity whereas breastfeeding with out first speaking to their healthcare supplier.
are taking different medicines together with prescription and over-the-counter medicines, nutritional vitamins, and natural dietary supplements. Trulicity might have an effect on the best way some medicines work and a few medicines might have an effect on the best way Trulicity works.
are taking different medicines to deal with diabetes, together with insulin or sulfonylureas.
If sufferers take an excessive amount of Trulicity, they need to name their healthcare supplier or go to the closest emergency room immediately.
The commonest unwanted effects with Trulicity might embrace: nausea, diarrhea, vomiting, belly ache and decreased urge for food. Sufferers ought to discuss to their healthcare supplier about any aspect impact that bothers them or doesn’t go away. These aren’t all of the potential unwanted effects of Trulicity. Sufferers ought to name their physician for medical recommendation about unwanted effects.
Sufferers are inspired to report unwanted effects of prescribed drugs to the FDA. Go to www.fda.gov/medwatch or name 1-800-FDA-1088.
Please click on to entry Prescribing Data, together with Boxed Warning about potential thyroid tumors together with thyroid most cancers, and Medicine Information.
Please see Directions for Use included with the pen.
DG PR ISI 12JUL2018
Roughly 30 million Americans4 and an estimated 425 million adults worldwide have diabetes.5 Kind 2 diabetes is the most typical kind internationally, accounting for an estimated 90 to 95 p.c of all diabetes instances in america alone.four Diabetes is a continual illness that happens when the physique doesn’t correctly produce or use the hormone insulin.
About Lilly Diabetes
Lilly has been a worldwide chief in diabetes care since 1923, after we launched the world’s first business insulin. As we speak we’re constructing upon this heritage by working to fulfill the various wants of individuals with diabetes and people who look after them. By means of analysis, collaboration and high quality manufacturing we attempt to make life higher for folks affected by diabetes. We provide a variety of therapies and a continued willpower to supply actual options—from medicines and applied sciences to assist packages and extra. For the newest updates, go to http://www.lillydiabetes.com/or comply with us on Twitter: @LillyDiabetes and Fb: LillyDiabetesUS.
About Eli Lilly and Firm
Lilly is a worldwide healthcare chief that unites caring with discovery to make life higher for folks all over the world. We have been based greater than a century in the past by a person dedicated to creating high-quality medicines that meet actual wants, and as we speak we stay true to that mission in all our work. Throughout the globe, Lilly staff work to find and convey life-changing medicines to those that want them, enhance the understanding and administration of illness, and provides again to communities by means of philanthropy and volunteerism. To be taught extra about Lilly, please go to us at www.lilly.com and www.lilly.com/newsroom/social-channels. P-LLY
Trulicity® is a registered trademark owned or licensed by Eli Lilly and Firm, its subsidiaries, or associates.
This press launch comprises forward-looking statements (as that time period is outlined within the Non-public Securities Litigation Reform Act of 1995) about Trulicity (dulaglutide) as a therapy for kind 2 diabetes and as a possible therapy for the discount of cardiovascular occasions and its security profile and displays Lilly’s present perception. Nevertheless, as with all pharmaceutical product, there are substantial dangers and uncertainties within the technique of improvement and commercialization. Amongst different issues, there may be no assure that future research outcomes shall be according to research findings to this point, that Trulicity will obtain extra regulatory approvals or that Trulicity will proceed to be commercially profitable. For additional dialogue of those and different dangers and uncertainties, see Lilly’s most up-to-date Type 10-Okay and Type 10-Q filings with america Securities and Change Fee. Besides as required by regulation, Lilly undertakes no responsibility to replace forward-looking statements to replicate occasions after the date of this launch.
Gerstein HC, Colhoun HM, et al. Dulaglutide and cardiovascular outcomes in kind 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. The Lancet. 2019. S0140-6736(19)31149-Three. Retrieved from https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31149-Three/fulltext.
Boye KS, Riddle MC, Gerstein HC, et al. Generalizability of Glucagon-Like Peptide-1 Receptor Agonist Cardiovascular Final result Trials to the General Kind 2 Diabetes Inhabitants in america. Diabetes Obes Metab 2019.
Gerstein HC, Colhoun HM, et al. Dulaglutide and renal outcomes in kind 2 diabetes: an exploratory evaluation of the REWIND randomised, placebo-controlled trial. 2019. S0140-6736(19)31150. Retrieved from: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31150-X/fulltext.
Facilities for Illness Management and Prevention. Nationwide Diabetes Statistics Report, 2017. Atlanta, GA: Facilities for Illness Management and Prevention, U.S. Dept of Well being and Human Providers; 2017.
Worldwide Diabetes Federation. IDF Diabetes Atlas, eighth edn. Brussels, Belgium: Worldwide Diabetes Federation, 2017. http://www.diabetesatlas.org.
Dani Barnhizer; firstname.lastname@example.org; (317) 607-6119 (Media)
Kevin Hern; email@example.com; (317) 277-1838 (Traders)
SOURCE Eli Lilly and Firm